Literature DB >> 6799533

High-performance liquid column and thin-layer chromatographic determination of human serum glibenclamide at therapeutic levels.

M Uihlein, N Sistovaris.   

Abstract

For glibenclamide bioavailability studies in serum, high-performance liquid column and thin-layer chromatographic methods were introduced. Both methods are specific, accurate and sensitive with detection limits of at least 5 ng of glibenclamide per ml of serum. Detection is performed in the ultraviolet at wavelengths of 200 nm for liquid chromatography or 300 nm for thin-layer chromatography. Serum levels determined by either method correlated well with those determined by an already existing radioimmunoassay. Some pharmacokinetic data were computed using a one-compartment open model.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6799533     DOI: 10.1016/s0378-4347(00)80359-x

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

2.  Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.

Authors:  P J Bijlstra; J A Lutterman; F G Russel; T Thien; P Smits
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

Review 3.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

4.  A radioimmunoassay for determination of glibenclamide and other sulfonylureas.

Authors:  W Heptner; M Badian; S Baudner; C Hellstern; R Irmisch; W Rupp; K Weimer; H Wissmann
Journal:  Pharm Res       Date:  1984-09       Impact factor: 4.200

Review 5.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.